BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1586374)

  • 1. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
    Menke G; Schnellhammer R; Rietbrock N
    Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
    Schaumann W
    Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
    Rietbrock N; Knoll J; Merz PG; Menke G
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers.
    Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E
    Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
    Geigenberger A; Degen J; Maier-Lenz H
    Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
    Leitold M; Laufen H
    Arzneimittelforschung; 1983; 33(8):1117-21. PubMed ID: 6685489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.
    Jiang Z; Wei C; Sun Z; Guo J; Li R; Zhang R; Yuan G; Guo R
    Drug Res (Stuttg); 2014 Feb; 64(2):73-8. PubMed ID: 23904215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
    Laufen H; Leitold M
    Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
    Vogt D; Trenk D; Bonn R; Jähnchen E
    Eur J Clin Pharmacol; 1994; 46(4):319-24. PubMed ID: 7957516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
    Laufen H; Aumann M; Leitold M
    Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma disposition and hemodynamic effects of a single oral dose of isosorbide dinitrate in human males and females.
    Nakatsu K; Brien JF; Savard G; Toffelmire EB; Abdollah H; Bennett BM; Marks GS
    Biopharm Drug Dispos; 1992 Jul; 13(5):357-67. PubMed ID: 1498268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
    Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
    Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.